⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Schisandra improves memory, attention, mood and brain fog in people. This page keeps it as a report of what people, websites or other media say.

Schisandra for Cognitive Function and Neuroprotection

Cognitive Function — scientific infographic poster

The neuroprotective and cognitive properties of Schisandra are anchored in three converging mechanisms documented in preclinical work over the past two decades: (1) acetylcholinesterase (AChE) inhibition by Schisandra lignans, mechanistically parallel to donepezil and rivastigmine but reversible and much milder, increasing synaptic acetylcholine in cortical and hippocampal projections; (2) schisandrin B-driven Nrf2 antioxidant pathway activation in cortical and hippocampal neurons, replicating the hepatic protective mechanism in central nervous system tissue; and (3) hippocampal neurogenesis and brain-derived neurotrophic factor (BDNF) up-regulation, supporting structural plasticity in the adult dentate gyrus. The human side rests on reports rather than trials: people describe modest help with memory and attention, while the studies behind the mechanisms are cell and animal work, including schisandrin B neuroprotection in amyloid-beta exposure models and a growing body of Korean and Chinese preclinical work in Alzheimer's, Parkinson's, and stroke recovery models. The cognitive evidence sits alongside the stress-protective and adaptogenic effects covered separately in the Adaptogenic and Stress deep-dive.


Table of Contents

  1. Reported Memory and Attention Effects in Middle-Aged Adults
  2. Schisandrin B Neuroprotection in Cell and Animal Work
  3. Acetylcholinesterase Inhibition Mechanism
  4. Alzheimer's Disease Preclinical Evidence
  5. Hippocampal Neurogenesis and Brain-Derived Neurotrophic Factor Up-Regulation
  6. Nrf2 Activation in Central Nervous System Tissue
  7. Parkinson's, Stroke, and Other Central Nervous System Models
  8. Mood, Anxiety, and Depression Effects
  9. Reported Uses for Cognitive Health
  10. What Human Trials of Schisandra Have Measured
  11. Cautions and Practical Notes
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Reported Memory and Attention Effects in Middle-Aged Adults

People and practitioners describe Schisandra as giving modest help with memory and attention in middle-aged adults who notice their memory slipping. The usual account is of better attention, working memory and processing speed, with less consistent effects on long-term memory and executive function. No published human trial of this was found for this page; the account rests on these reports and on the cell and animal work in the sections below. In people, these abilities are usually measured with tests such as:

The overall pattern is described as consistent with the adaptogen literature in the Adaptogenic and Stress deep-dive: modest but reproducible cognitive support that emerges over weeks rather than minutes, distinguishable from the acute effects of stimulants like caffeine.

Back to Table of Contents

Schisandrin B Neuroprotection in Cell and Animal Work

The single most extensively studied molecule in the Schisandra cognitive-neuroscience literature is schisandrin B. Laboratory papers describe schisandrin B at low micromolar concentrations protecting cultured neurons against multiple injury models. In one, pretreatment raised the survival of rat cortical neurons exposed to amyloid-beta (Wang and Wang 2009); in another, 5 and 15 micromolar reduced cell death in differentiated PC12 cells challenged with a mitochondrial toxin (Lam and Ko 2012). The injury models described include:

The unifying mechanism across these injury models is preservation of mitochondrial integrity and prevention of the mitochondrial permeability transition — the same effect documented in hepatocyte studies, transposed to neuronal tissue. Schisandrin B stabilizes mitochondrial inner membrane and prevents cytochrome c release, maintaining adenosine triphosphate (ATP) production and preventing initiation of the intrinsic apoptotic cascade. The neuronal preservation effect is described as occurring at concentrations reached in plasma after standard oral dosing of standardized extract. The neuron work cited here is cell culture, and a 2025 review notes challenges in the absorption, distribution, metabolism and excretion of these lignans that affect how much reaches the body.

Back to Table of Contents

Acetylcholinesterase Inhibition Mechanism

A second mechanism with direct cognitive relevance is acetylcholinesterase (AChE) inhibition by schisandrin lignans. Acetylcholinesterase is the enzyme that hydrolyzes synaptic acetylcholine, terminating cholinergic neurotransmission. Inhibition of AChE prolongs and amplifies cholinergic signaling at central nervous system synapses — the molecular basis of the cholinesterase-inhibitor drug class (donepezil, rivastigmine, galantamine) used in Alzheimer's disease.

In a 2007 laboratory study of fourteen lignans from the fruit, five entirely inhibited AChE in a dose-dependent way: gomisin C, gomisin G, gomisin D, schisandrol B and gomisin A, at IC50 values (the amount that blocks half the enzyme) of 6.55 to 13.28 micromolar. These are the lignans with both methylenedioxy and hydroxyl groups on their ring. Schisandrin A, schisandrin B and schisantherin A are not among the actives that study names. The inhibition is described in secondary accounts as:

Animal work points the same way. In rats, schizandrin at 1 and 10 mg/kg by mouth reversed the memory loss caused by the drug scopolamine (Egashira 2008). In mice injected with amyloid-beta, schisandrin at 4, 12 and 36 mg/kg improved memory in maze tests (Hu 2012). None of this has been tested in people for memory.

Two things follow. First, the AChE inhibition is offered as a mechanism for the cognitive benefits people report with memory complaints, by augmenting endogenous cortical and hippocampal cholinergic signaling. Second, the AChE inhibition raises a theoretical drug-interaction concern for people on prescription donepezil, rivastigmine, or galantamine: added effects on synaptic acetylcholine could theoretically increase cholinergic side effects, namely a slow heartbeat (bradycardia), more stomach acid and frequent urination.

For more on the cholinergic pathways and their pharmacology, see related discussions on our Herbs index for Bacopa monnieri and other AChE-modulating botanicals.

Back to Table of Contents

Alzheimer's Disease Preclinical Evidence

The preclinical evidence base for Schisandra in Alzheimer's disease models has grown substantially over the past 15 years. The principal lines of evidence:

  1. Amyloid-beta protection (in vitro) — as discussed above, schisandrin B reduces Abeta-induced neuronal death in PC12 cells, primary cortical neurons, and hippocampal slice cultures across multiple groups and laboratories
  2. Amyloid-beta protection (in vivo) — in 3xTg-AD and APP/PS1 transgenic mouse models of Alzheimer's, oral Schisandra extract reduces hippocampal amyloid plaque load, reduces tau hyperphosphorylation, and improves Morris water maze and novel-object-recognition memory performance
  3. BACE-1 (beta-secretase) inhibition — some Schisandra lignans modestly inhibit beta-secretase, the enzyme that performs the rate-limiting cleavage of amyloid precursor protein to generate amyloid-beta. This is the same enzyme target as several failed Alzheimer's drug-development programs (verubecestat, atabecestat), though Schisandra's effect is much weaker and may not be clinically relevant in isolation
  4. Neuroinflammation reduction — microglial activation and inflammatory cytokine release (tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6) in the Alzheimer's brain are reduced by Schisandra in animal models, mechanistically through NF-kappa-B suppression and Nrf2 activation
  5. AChE inhibition (already discussed) contributes parallel cholinergic support
  6. A 2024 rat study — a diet with 0.5% Schisandra fruit water extract for seven weeks reduced amyloid-beta deposits, inflammation and memory deficits after amyloid was infused into the hippocampus, and lowered hippocampal acetylcholinesterase activity. This is an animal result (Yang 2024)

The translational question — whether preclinical Alzheimer's protection translates to clinical benefit in human patients — remains unanswered. There are no large randomized trials of Schisandra in clinical Alzheimer's disease populations. The preclinical evidence supports investigation but does not yet justify a clinical recommendation for treatment or prevention of Alzheimer's disease. Most clinical use of Schisandra in cognitive applications targets the much larger population of cognitively healthy older adults concerned about cognitive aging, rather than people diagnosed with Alzheimer's disease.

Back to Table of Contents

Hippocampal Neurogenesis and Brain-Derived Neurotrophic Factor Up-Regulation

One of the more interesting recent mechanism findings is that Schisandra promotes adult hippocampal neurogenesis in animal models. The dentate gyrus of the hippocampus is one of the two adult brain regions where new neurons are continuously generated from neural progenitor cells throughout adult life (the other being the subventricular zone of the lateral ventricles). Hippocampal neurogenesis is critical for pattern separation in episodic memory and for adaptive responses to environmental enrichment, exercise, and antidepressant treatment.

Several mechanisms converge to support hippocampal neurogenesis under Schisandra exposure:

The functional consequence in behavioral testing is improved performance on hippocampus-dependent tasks — spatial navigation (Morris water maze), pattern separation (modified novel-object recognition), and contextual fear discrimination. These behavioral effects emerge over weeks of chronic dosing, consistent with the time course of new neuron maturation and integration into hippocampal circuitry.

Back to Table of Contents

Nrf2 Activation in Central Nervous System Tissue

The same Keap1/Nrf2 antioxidant-response pathway that drives the hepatic protective effect (discussed in detail in the Liver Protection deep-dive) operates in central nervous system (CNS) tissue with parallel effects. Schisandrin B activates Nrf2 in cortical neurons, hippocampal neurons, microglia, and astrocytes, with consequent up-regulation of glutathione synthesis (GCLC, GCLM), heme oxygenase-1 (HO-1), nicotinamide adenine dinucleotide phosphate (NAD(P)H) quinone oxidoreductase 1 (NQO1), and thioredoxin.

The central nervous system relevance of Nrf2 activation is substantial. Several major neurodegenerative diseases involve chronic oxidative stress as a contributing mechanism:

The pharmaceutical drug dimethyl fumarate (used in multiple sclerosis) is essentially a clinically validated Nrf2 activator, providing pharmaceutical proof-of-concept that Nrf2 pathway activation has neurological clinical relevance. Proponents describe Schisandra's lignan-driven Nrf2 activation as operating on the same principle, with a much broader safety profile but also a much smaller effect; no human effect size has been measured.

Back to Table of Contents

Parkinson's, Stroke, and Other Central Nervous System Models

Beyond Alzheimer's disease, Schisandra has been studied in preclinical models of several other central nervous system conditions:

None of these central nervous system applications have been validated in clinical trials at the level required to enter clinical practice. They constitute a mechanistically coherent preclinical program suggesting that Schisandra's broader neuroprotective mechanism may have clinical relevance across multiple neurodegenerative and acute central nervous system conditions, but the translational gap remains substantial.

Back to Table of Contents

Mood, Anxiety, and Depression Effects

The cognitive and adaptogenic effects of Schisandra blur into mood-related effects, particularly in the context of stress-related fatigue and burnout discussed in the Adaptogenic and Stress deep-dive. Several specific mood-related mechanisms are documented:

Schisandra is sometimes included in adaptogen combination formulas marketed for mild-to-moderate depression and anxiety, and users and practitioners report easing of low mood and anxiety; no trial of this was found for this page. Schisandra is not established as a replacement for antidepressant or anxiety medicines in major depressive disorder or generalized anxiety disorder; practitioners describe it as an add-on for mild-to-moderate symptoms.

For more on this domain, see Depression and related psychiatric pages.

Back to Table of Contents

Reported Uses for Cognitive Health

Uses described by practitioners and users, none of them backed by a human cognitive trial found for this page:

The regimen practitioners describe: standardized extract providing 100-500 mg of total lignans daily, in divided doses, taken in morning and early afternoon, with effects reported over 4-8 weeks, a review at 8-12 weeks, and courses of 3-6 months with planned breaks. No trial of memory has tested this amount; the only trial doses found are 1 g of extract a day in the muscle-strength trials below. Baseline and follow-up measures (a simple home tool such as the Self-Administered Gerocognitive Exam (SAGE) or a self-administered version of the Montreal Cognitive Assessment (MoCA)) can show whether a felt improvement matches a measured change.

Back to Table of Contents

What Human Trials of Schisandra Have Measured

The placebo-controlled human trials found for this page measured things other than memory. No placebo-controlled trial of Schisandra alone for memory was found.

Back to Table of Contents

Cautions and Practical Notes

Back to Table of Contents

Key Research Papers

  1. Chen WW, He RR, Li YF, et al. (2011). Pharmacological studies on the anxiolytic effect of standardized Schisandra lignans extract on restraint-stressed mice. Phytomedicine 18(13):1144-1147. — PubMed PMID: 21757327
  2. Lam PY, Ko KM (2012). Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases. Oxidative Medicine and Cellular Longevity 2012:250825. — PubMed PMID: 22666518
  3. Hu D, Cao Y, He R, et al. (2012). Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Abeta1-42-induced memory impairment in mice. Oxidative Medicine and Cellular Longevity. — PubMed PMID: 22829961
  4. Sa F, Zhang LQ, Chong CM, et al. (2015). Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neuroscience Letters. — PubMed PMID: 25770828
  5. Mocan A, Schafberg M, Crisan G, Rohn S (2016). Determination of lignans and phenolic components of Schisandra chinensis (Turcz.) Baill. using HPLC-ESI-ToF-MS and HPLC-online TEAC: Contribution of individual components to overall antioxidant activity and comparison with traditional antioxidant assays. Journal of Functional Foods 24:579-594. — doi:10.1016/j.jff.2016.05.007
  6. Lee TH, Jung CH, Lee DH (2012). Neuroprotective effects of Schisandrin B against transient focal cerebral ischemia in Sprague-Dawley rats. Food and Chemical Toxicology. — PubMed PMID: 22960133
  7. Wang B, Wang XM (2009). Schisandrin B protects rat cortical neurons against Abeta1-42-induced neurotoxicity. Pharmazie. — PubMed PMID: 19694182
  8. Egashira N, Kurauchi K, Iwasaki K, et al. (2008). Schizandrin reverses memory impairment in rats. Phytotherapy Research. — PubMed PMID: 17705144
  9. Lam PY, Ko KM (2012). Beneficial effect of (-)schisandrin B against 3-nitropropionic acid-induced cell death in PC12 cells. Biofactors 38(3):219-225. — PubMed PMID: 22488872
  10. Chen N, Chiu PY, Ko KM (2008). Schisandrin B enhances cerebral mitochondrial antioxidant status and structural integrity, and protects against cerebral ischemia/reperfusion injury in rats. Biological and Pharmaceutical Bulletin. — PubMed PMID: 18591780
  11. Hung TM, Na M, Min BS, et al. (2007). Acetylcholinesterase inhibitory effect of lignans isolated from Schizandra chinensis. Archives of Pharmacal Research 30(6):685-690. — PubMed PMID: 17679544
  12. Yang HJ, Zhang T, Kim MJ, et al. (2024). Efficacy and Mechanism of Schisandra chinensis Fructus Water Extract in Alzheimer's Disease: Insights from Network Pharmacology and Validation in an Amyloid-β Infused Animal Model. Nutrients 16(21). — PubMed PMID: 39519586
  13. Cho YH, Lee SY, Lee CH, Park JH, So YS (2021). Effect of Schisandra chinensis Baillon extracts and regular low-intensity exercise on muscle strength and mass in older adults: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition 113(6):1440-1446. — PubMed PMID: 33710261
  14. Park J, Han S, Park H (2020). Effect of Schisandra Chinensis Extract Supplementation on Quadriceps Muscle Strength and Fatigue in Adult Women: A Randomized, Double-Blind, Placebo-Controlled Trial. International Journal of Environmental Research and Public Health 17(7). — PubMed PMID: 32260466
  15. Park JY, Kim KH (2016). A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms. Climacteric 19(6):574-580. — PubMed PMID: 27763802
  16. Zhang F, Zhai J, Weng N, Gao J, Yin J, Chen W (2022). A Comprehensive Review of the Main Lignan Components of Schisandra chinensis (North Wu Wei Zi) and Schisandra sphenanthera (South Wu Wei Zi) and the Lignan-Induced Drug-Drug Interactions Based on the Inhibition of Cytochrome P450 and P-Glycoprotein Activities. Frontiers in Pharmacology 13:816036. — PubMed PMID: 35359848
  17. Ehambarampillai D, Wan MLY (2025). A comprehensive review of Schisandra chinensis lignans: pharmacokinetics, pharmacological mechanisms, and future prospects in disease prevention and treatment. Chinese Medicine 20(1):47. — PubMed PMID: 40205412
  18. Xiang Q, Yang Y, Li G, et al. (2025). Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication. Drug Design, Development and Therapy 19:8375-8389. — PubMed PMID: 40980420

PubMed Topic Searches

  1. PubMed: Schisandra cognitive / memory
  2. PubMed: Schisandrin B / neuroprotection / amyloid
  3. PubMed: Schisandra AChE inhibition
  4. PubMed: Schisandra hippocampal neurogenesis / BDNF
  5. PubMed: Schisandra Parkinson's / dopaminergic

Back to Table of Contents

Connections

Back to Table of Contents